Searched for
PSORIASIS DRUG
How an Australian connection helped Shaily Mehrotra build a Rs 1,500-crore Indian skincare brandA gap in science-backed skincare products in the Indian market prompted Shaily Mehrotra to start Fixderma, with an aim to solve common skin...- Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration dealSun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. ...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Sun Pharma shares jump over 9% after firm announces $12 billion Organon acquisitionSun Pharmaceutical Industries' shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in ...
- ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...
- Alembic Pharma gets USFDA nod for generic cancer, arthritis injectionAlembic Pharmaceuticals has received final approval from the US Food and Drug Administration for its generic methotrexate injection, used t...
- Sun Pharma shares tumble 4% as firm closes in on $12-billion Organon acquisition. What’s spooking investors?Shares of Sun Pharmaceutical Industries fell sharply after ET reported the company had submitted a $12-billion binding offer for Organon & ...
- Sun Pharma closes in on Organon buy, gets set for $12 billion binding bidSun Pharmaceutical Industries is nearing a $12 billion acquisition of Organon & Co, marking its most significant overseas expansion. Follow...
- Sun Pharma’s Ilumya expansion bid gets USFDA nod for reviewSun Pharmaceutical has received a significant approval from the USFDA. The company's innovative drug, Ilumya, is now being considered for t...
- Sun Pharma Advanced Research shares tank 20% after psoriasis drug fails Phase 2 trialsSun Pharma Advanced Research Company (SPARC) psoriasis drug, Vibozilimod (SCD-044), failed to meet primary endpoints in Phase 2 trials for ...
- Eli Lilly forays into dermatological space with launch of psoriasis drugEli Lilly has launched a new drug to treat moderate-to-severe plaque psoriasis in India. The drug, Copellor, is designed to specifically ta...
- Sun Pharma climbs over 3% after USFDA drug nodThe company informed stock exchanges about the USFDA nod after market hours of Wednesday.
- Tildra approval to give sentimental push to Sun PharmaThe drug which will be sold under the brand name Ilumya is expected to treat adults for moderate to severe plaque psoriasis, an autoimmune ...
- Sun Pharma gets USFDA nod for plaque psoriasis drugThe FDA approval of the drug was supported by data from the pivotal phase-3 resurface clinical development program, it said.
- Sun Pharma announces details of psoriasis drug trialsTildrakizumab is a monoclonal antibody designed to control the pathogenic cells responsible for the inflammatory process of psoriasis with ...
- Sun Pharma signs licening pact with spanish firm Almirall for psoriasis drugIn return, the Indian company will receive an initial upfront payment of $50 million and be eligible for development and regulatory milesto...
- GVK Bio, Akaal Pharma extend partnership for drug developmentGVK Biosciences was under the regulatory scanner of European drug regulators a few months ago.
- Biocon to launch psoriasis drug novel biologic in JulyThe company had received marketing authorisation for Itolizumab from the Drugs Controller General of India (DCGI) in January, 2013.
- Biocon gets DCGI approval to market anti-psoriasis drug, Itolizumab"The company has received market authorisation from the DCGI for its novel biologic Itolizumab, for treatment of chronic plaque psoriasis,"...
- Looking for global partner for psoriasis drug: Kiran Mazumdar Shaw, BioconThe plan is that the India drug will launched as an intravenous infusion and it has been indicated for psoriasis, says Kiran Mazumdar Shaw.
Load More
